LetterKeratoacanthomas associated with sorafenib therapy
References (4)
- ClinicalTrials.gov [database online]. Bethesda, MD: National Library of Medicine; 2006. Available at:...
- et al.
Raf kinase inhibitors in oncology
Onkologie
(2005)
Cited by (85)
Emergence of ocular toxicities associated with novel anticancer therapeutics: What the oncologist needs to know
2022, Cancer Treatment ReviewsCitation Excerpt :Sunitinib has been associated with retinal detachments (at least 24 cases) [54]. Sorafenib is associated with squamoproliferative lesions, such as keratoacanthomas, and squamous cell carcinoma affecting the eyelid [55], retinal detachments (at least 7 reported cases), and retinal tears (at least 2 reported cases) in case reports [54,56]. Management: Periorbital edema from imatinib is typically mild and can be managed conservatively.
Anticancer therapies associated with secondary cutaneous malignancies: A review of the literature
2020, Journal of the American Academy of DermatologyCutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane
2015, Journal of the American Academy of DermatologyFármacos antiangiogénicos y piel: Efectos cutáneos adversos de sorafenib, sunitinib y bevacizumab
2014, Actas Dermo-SifiliograficasCutaneous toxicities of BRAF inhibitors: Clinical and pathological challenges and call to action
2013, Critical Reviews in Oncology/HematologyCitation Excerpt :It is well known that sorafenib, vemurafenib, and DABRAFENIB are associated with the development of skin squamous cell proliferations. Indeed, it has been reported that the appearance of single or multiple cutaneous KA and SCC arises in 6–7% of patients treated with sorafenib [14–18], while the induction of KA and SCC is even more frequent (15–25% of patients) with vemurafenib and dabrafenib [3,9–11]. As regards sorafenib-induced KA and SCC, to our best knowledge, there are 5 published studies reporting this type of toxicity [14–18].
Targeted therapy in melanoma
2013, Clinics in DermatologyCitation Excerpt :The lesions of BRAF inhibitor therapy are classically bilateral and symmetrical, predominantly located on pressure or friction areas, and rapidly become hyperkeratotic. An erythematous ring frequently surrounds the hyperkeratotic lesions.83-89 Areas of hyperkeratosis may occasionally become painful, which may eventually interfere with everyday activities, such as walking or holding objects.